Figure S5 from The Oncolytic Adenovirus XVir-N-31 Joins Forces with CDK4/6 Inhibition Augmenting Innate and Adaptive Antitumor Immunity in Ewing Sarcoma

Figure S5 from The Oncolytic Adenovirus XVir-N-31 Joins Forces with CDK4/6 Inhibition Augmenting Innate and Adaptive Antitumor Immunity in Ewing Sarcoma

<p>Supplemental Figure 5: Combination therapy of XVir-N-31 and CDK4/6 inhibitor LEE011 induces calreticulin (CALR) surface expression and increases phagocytosis in vitro.</p>

Kaydedildi:

Detaylı Bibliyografya
Yazar:	Sebastian Johannes Schober (14971891) (author)
Diğer Yazarlar:	Caroline Schoening (14971894) (author), Jennifer Eck (14971897) (author), Charlotte Middendorf (14971900) (author), Julia Lutsch (14971903) (author), Pia Knoch (14971906) (author), Anna Josefine von Ofen (14971909) (author), Hendrik Gassmann (14971912) (author), Melanie Thiede (14971915) (author), Julia Hauer (14971918) (author), Andreas Kolk (14971921) (author), Klaus Mantwill (14971924) (author), Jürgen E. Gschwend (14971927) (author), Stefan E.G. Burdach (14971930) (author), Roman Nawroth (14971933) (author), Uwe Thiel (14971936) (author), Per Sonne Holm (14971939) (author)
Baskı/Yayın Bilgisi:	2025
Konular:	Cancer Therapeutic Research and Development Immuno-oncology Immunotherapy Combination immunotherapy Pediatric Cancers Sarcomas Translational Research
Etiketler:	Etiketle Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller

Figure S1 from The Oncolytic Adenovirus XVir-N-31 Joins Forces with CDK4/6 Inhibition Augmenting Innate and Adaptive Antitumor Immunity in Ewing Sarcoma
Yazar:: Sebastian Johannes Schober (14971891)
Baskı/Yayın Bilgisi: (2025)

Figure S2 from The Oncolytic Adenovirus XVir-N-31 Joins Forces with CDK4/6 Inhibition Augmenting Innate and Adaptive Antitumor Immunity in Ewing Sarcoma
Yazar:: Sebastian Johannes Schober (14971891)
Baskı/Yayın Bilgisi: (2025)

Figure S3 from The Oncolytic Adenovirus XVir-N-31 Joins Forces with CDK4/6 Inhibition Augmenting Innate and Adaptive Antitumor Immunity in Ewing Sarcoma
Yazar:: Sebastian Johannes Schober (14971891)
Baskı/Yayın Bilgisi: (2025)

Figure S4 from The Oncolytic Adenovirus XVir-N-31 Joins Forces with CDK4/6 Inhibition Augmenting Innate and Adaptive Antitumor Immunity in Ewing Sarcoma
Yazar:: Sebastian Johannes Schober (14971891)
Baskı/Yayın Bilgisi: (2025)

Supplementary Data from Attenuation of Sialylation Augments Antitumor Immunity and Improves Response to Immunotherapy in Ovarian Cancer
Yazar:: Kankan Cao (16437263)
Baskı/Yayın Bilgisi: (2025)

Figure S1 from PARP Inhibition Induces Synthetic Lethality and Adaptive Immunity in LKB1-Mutant Lung Cancer
Yazar:: Li-Li Long (14963775)
Baskı/Yayın Bilgisi: (2025)

Figure S2 from PARP Inhibition Induces Synthetic Lethality and Adaptive Immunity in LKB1-Mutant Lung Cancer
Yazar:: Li-Li Long (14963775)
Baskı/Yayın Bilgisi: (2025)

Figure S3 from PARP Inhibition Induces Synthetic Lethality and Adaptive Immunity in LKB1-Mutant Lung Cancer
Yazar:: Li-Li Long (14963775)
Baskı/Yayın Bilgisi: (2025)

Figure S4 from PARP Inhibition Induces Synthetic Lethality and Adaptive Immunity in LKB1-Mutant Lung Cancer
Yazar:: Li-Li Long (14963775)
Baskı/Yayın Bilgisi: (2025)

Figure S5 from PARP Inhibition Induces Synthetic Lethality and Adaptive Immunity in LKB1-Mutant Lung Cancer
Yazar:: Li-Li Long (14963775)
Baskı/Yayın Bilgisi: (2025)

Figure S6 from PARP Inhibition Induces Synthetic Lethality and Adaptive Immunity in LKB1-Mutant Lung Cancer
Yazar:: Li-Li Long (14963775)
Baskı/Yayın Bilgisi: (2025)

Figure S7 from PARP Inhibition Induces Synthetic Lethality and Adaptive Immunity in LKB1-Mutant Lung Cancer
Yazar:: Li-Li Long (14963775)
Baskı/Yayın Bilgisi: (2025)

Supplementary Table 1 from PARP Inhibition Induces Synthetic Lethality and Adaptive Immunity in LKB1-Mutant Lung Cancer
Yazar:: Li-Li Long (14963775)
Baskı/Yayın Bilgisi: (2025)

Supplementary Table 2 from PARP Inhibition Induces Synthetic Lethality and Adaptive Immunity in LKB1-Mutant Lung Cancer
Yazar:: Li-Li Long (14963775)
Baskı/Yayın Bilgisi: (2025)

Supplementary Fig. S1 from The mTOR Signaling Pathway Interacts with the ER Stress Response and the Unfolded Protein Response in Cancer
Yazar:: Sahar Mafi (16721657)
Baskı/Yayın Bilgisi: (2025)

Supplementary Fig. S2 from The mTOR Signaling Pathway Interacts with the ER Stress Response and the Unfolded Protein Response in Cancer
Yazar:: Sahar Mafi (16721657)
Baskı/Yayın Bilgisi: (2025)

Figure S1 from Vaccination with Designed Neopeptides Induces Intratumoral, Cross-reactive CD4<sup>+</sup> T-cell Responses in Glioblastoma
Yazar:: Jian Wang (15048011)
Baskı/Yayın Bilgisi: (2025)

Figure S2 from Vaccination with Designed Neopeptides Induces Intratumoral, Cross-reactive CD4<sup>+</sup> T-cell Responses in Glioblastoma
Yazar:: Jian Wang (15048011)
Baskı/Yayın Bilgisi: (2025)

Figure S3 from Vaccination with Designed Neopeptides Induces Intratumoral, Cross-reactive CD4<sup>+</sup> T-cell Responses in Glioblastoma
Yazar:: Jian Wang (15048011)
Baskı/Yayın Bilgisi: (2025)

Figure S4 from Vaccination with Designed Neopeptides Induces Intratumoral, Cross-reactive CD4<sup>+</sup> T-cell Responses in Glioblastoma
Yazar:: Jian Wang (15048011)
Baskı/Yayın Bilgisi: (2025)

Figure S5 from Vaccination with Designed Neopeptides Induces Intratumoral, Cross-reactive CD4<sup>+</sup> T-cell Responses in Glioblastoma
Yazar:: Jian Wang (15048011)
Baskı/Yayın Bilgisi: (2025)

Figure S6 from Vaccination with Designed Neopeptides Induces Intratumoral, Cross-reactive CD4<sup>+</sup> T-cell Responses in Glioblastoma
Yazar:: Jian Wang (15048011)
Baskı/Yayın Bilgisi: (2025)

Figure S7 from Vaccination with Designed Neopeptides Induces Intratumoral, Cross-reactive CD4<sup>+</sup> T-cell Responses in Glioblastoma
Yazar:: Jian Wang (15048011)
Baskı/Yayın Bilgisi: (2025)

Figure S8 from Vaccination with Designed Neopeptides Induces Intratumoral, Cross-reactive CD4<sup>+</sup> T-cell Responses in Glioblastoma
Yazar:: Jian Wang (15048011)
Baskı/Yayın Bilgisi: (2025)

Table S2 from Vaccination with Designed Neopeptides Induces Intratumoral, Cross-reactive CD4<sup>+</sup> T-cell Responses in Glioblastoma
Yazar:: Jian Wang (15048011)
Baskı/Yayın Bilgisi: (2025)

Table S4 from Vaccination with Designed Neopeptides Induces Intratumoral, Cross-reactive CD4<sup>+</sup> T-cell Responses in Glioblastoma
Yazar:: Jian Wang (15048011)
Baskı/Yayın Bilgisi: (2025)

Supplementary figures and tables FTS1 from Intraperitoneal Monocytes plus IFNs as a Novel Cellular Immunotherapy for Ovarian Cancer: Mechanistic Characterization and Results from a Phase I Clinical Trial
Yazar:: Daniel S. Green (15047598)
Baskı/Yayın Bilgisi: (2025)

Supplementary Table 1 from Phase I Study of Androgen Deprivation Therapy in Combination with Anti–PD-1 in Melanoma Patients Pretreated with Anti–PD-1
Yazar:: Caroline Robert (15032672)
Baskı/Yayın Bilgisi: (2025)

Supplementary Table 2 from Phase I Study of Androgen Deprivation Therapy in Combination with Anti–PD-1 in Melanoma Patients Pretreated with Anti–PD-1
Yazar:: Caroline Robert (15032672)
Baskı/Yayın Bilgisi: (2025)

Supplementary Table 3 from Phase I Study of Androgen Deprivation Therapy in Combination with Anti–PD-1 in Melanoma Patients Pretreated with Anti–PD-1
Yazar:: Caroline Robert (15032672)
Baskı/Yayın Bilgisi: (2025)

Supplementary Table 4 from Phase I Study of Androgen Deprivation Therapy in Combination with Anti–PD-1 in Melanoma Patients Pretreated with Anti–PD-1
Yazar:: Caroline Robert (15032672)
Baskı/Yayın Bilgisi: (2025)

Diversity of augmented graphs.
Yazar:: Hossein Rafieizadeh (22676722)
Baskı/Yayın Bilgisi: (2025)

Supplementary Table S1 from Neoantigen Targetability in Progressive Advanced Melanoma
Yazar:: Jitske van den Bulk (17142147)
Baskı/Yayın Bilgisi: (2025)

Supplementary Table S2 from Neoantigen Targetability in Progressive Advanced Melanoma
Yazar:: Jitske van den Bulk (17142147)
Baskı/Yayın Bilgisi: (2025)

Supplementary Table S3 from Neoantigen Targetability in Progressive Advanced Melanoma
Yazar:: Jitske van den Bulk (17142147)
Baskı/Yayın Bilgisi: (2025)

Supplementary Table S4 from Neoantigen Targetability in Progressive Advanced Melanoma
Yazar:: Jitske van den Bulk (17142147)
Baskı/Yayın Bilgisi: (2025)

Supplementary Table S5 from Neoantigen Targetability in Progressive Advanced Melanoma
Yazar:: Jitske van den Bulk (17142147)
Baskı/Yayın Bilgisi: (2025)

Supplementary Data 1 from Uncoupling CD4<sup>+</sup> TIL-Mediated Tumor Killing from JAK-Signaling in Melanoma
Yazar:: Arianna Draghi (15126339)
Baskı/Yayın Bilgisi: (2025)

Supplementary Data 2 from Uncoupling CD4<sup>+</sup> TIL-Mediated Tumor Killing from JAK-Signaling in Melanoma
Yazar:: Arianna Draghi (15126339)
Baskı/Yayın Bilgisi: (2025)

Supplementary Data 3 from Uncoupling CD4<sup>+</sup> TIL-Mediated Tumor Killing from JAK-Signaling in Melanoma
Yazar:: Arianna Draghi (15126339)
Baskı/Yayın Bilgisi: (2025)

Cannot write session to /tmp/vufind_sessions/sess_i9ungqmdu13mt245k71v5mqmco